Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CCCC 
C4 Therapeutics Inc (CCCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: CCCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.8
1 Year Target Price $15.8
| 4 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.3% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 121.42M USD | Price to earnings Ratio - | 1Y Target Price 15.8 |
Price to earnings Ratio - | 1Y Target Price 15.8 | ||
Volume (30-day avg) 8 | Beta 2.95 | 52 Weeks Range 1.08 - 7.66 | Updated Date 07/8/2025 |
52 Weeks Range 1.08 - 7.66 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -259.6% | Operating Margin (TTM) -402.93% |
Management Effectiveness
Return on Assets (TTM) -20.3% | Return on Equity (TTM) -45.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -42790234 | Price to Sales(TTM) 3.05 |
Enterprise Value -42790234 | Price to Sales(TTM) 3.05 | ||
Enterprise Value to Revenue 8.85 | Enterprise Value to EBITDA -0.42 | Shares Outstanding 71007104 | Shares Floating 49730521 |
Shares Outstanding 71007104 | Shares Floating 49730521 | ||
Percent Insiders 9.79 | Percent Institutions 91.87 |
Upturn AI SWOT
C4 Therapeutics Inc
Company Overview
History and Background
C4 Therapeutics, Inc. (CCCC) was founded in 2011 and is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapeutics. They aim to create novel therapies for cancer and other diseases. Their approach is centered around utilizing the ubiquitin-proteasome system to selectively degrade disease-causing proteins.
Core Business Areas
- Targeted Protein Degradation (TPD): C4 Therapeutics' primary focus is on developing small-molecule drugs that induce the degradation of disease-causing proteins. Their approach is applicable across various therapeutic areas, with a focus on oncology and other diseases.
- Drug Discovery and Development: The company engages in all stages of drug discovery and development, from target identification and validation to preclinical studies and clinical trials.
- Collaboration and Partnerships: C4 Therapeutics collaborates with other pharmaceutical companies to expand their pipeline and accelerate drug development.
Leadership and Structure
Andrew Hirsch serves as the President and CEO. The organizational structure includes research and development, clinical operations, business development, and corporate functions.
Top Products and Market Share
Key Offerings
- CFT7455: An oral MonoDAC degrader of IKZF1/3, is in Phase 1/2 clinical trials for relapsed/refractory multiple myeloma and relapsed/refractory non-Hodgkin lymphoma. No current market share or revenue information is publicly available as it is in clinical development. Competitors in myeloma include companies developing proteasome inhibitors, immunomodulatory drugs, and antibody therapies. Competitors in lymphoma are the many established therapies for lymphoma patients.
- CFT1946: An oral BiDAC degrader of BRD9, is in Phase 1 clinical trials for SMARCA4-mutant solid tumors, including non-small cell lung cancer. No current market share or revenue information is publicly available as it is in clinical development. Competitors include companies developing SMARCA4 inhibitors and various chemotherapy regimens.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and lengthy regulatory approval processes. Targeted protein degradation is an emerging field with significant potential to address previously undruggable targets.
Positioning
C4 Therapeutics is positioned as a leader in the targeted protein degradation field, with a proprietary platform and a growing pipeline of drug candidates. Their competitive advantage lies in their expertise in designing and developing degrader molecules.
Total Addressable Market (TAM)
The TAM for targeted protein degradation therapies is potentially very large, addressing various diseases with currently unmet medical needs. The specific TAM for C4 Therapeutics' current pipeline depends on the successful development and approval of their drug candidates. Precise TAM estimates are difficult to provide without specific market forecasts for each indication.
Upturn SWOT Analysis
Strengths
- Proprietary targeted protein degradation platform
- Strong scientific expertise and experienced management team
- Growing pipeline of drug candidates
- Strategic collaborations with pharmaceutical companies
Weaknesses
- Early stage of development with limited clinical data
- High reliance on preclinical data and potential clinical trial risks
- Significant cash burn and reliance on future funding
- Competition from other companies in the TPD space
Opportunities
- Potential to develop first-in-class TPD therapies
- Expansion of pipeline into new therapeutic areas
- Strategic partnerships to accelerate drug development
- Increasing adoption of TPD as a therapeutic modality
Threats
- Clinical trial failures and regulatory setbacks
- Competition from established pharmaceutical companies
- Patent challenges and intellectual property disputes
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- KYMR
- ARRY
Competitive Landscape
C4 Therapeutics' competitive advantage lies in its specific TPD platform. However, it faces competition from companies with established pipelines and greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical progress and strategic partnerships.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates can be found on financial websites, but are subject to change based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for CFT7455 and CFT1946 and expanding its pipeline through internal discovery efforts.
Summary
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation, an emerging therapeutic modality. While the company has a proprietary platform and growing pipeline, it faces significant risks related to clinical trial outcomes and financial sustainability. Successful development and commercialization of its drug candidates are crucial for its future success. The early stage company needs to be cognizant of potential market entry from incumbents with superior marketing, distribution, and access to capital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- C4 Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Company press releases
- Financial news websites
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may not reflect actual figures. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About C4 Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-10-02 | CEO, President & Director Mr. Andrew J. Hirsch M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.c4therapeutics.com |
Full time employees 110 | Website https://www.c4therapeutics.com | ||
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.